A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Official Title

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumours


This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumours.

Trial Description

Primary Outcome:

  • Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE)
  • Number of participants with dose-limiting toxicity (DLT), as defined in the protoocol
  • Preliminary anti-tumour activity of AZD7789
Secondary Outcome:
  • Objective response rate
  • Disease control rate
  • Duration of response
  • Progression-free survival
  • Overall survival
  • Pharmacokinetics of AZD7789: Maximum plasma concentration of the study drug (Cmax)
  • Immunogenicity of AZD7789
  • Pharmacokinetics of AZD7789: Area Under the concentration-time curve (AUC)
  • Pharmacokinetics of AZD7789: Clearance
  • Pharmacokinetics of AZD7789: Terminal elimination half-life (t 1/2)
This first time in patients, open-label, multi-centre study will have AZD7789 administered intravenously (IV) to participants with advanced solid tumours. This study will have 2 parts: Part A which will have dose escalation cohorts and Part B which will have the dose expansion cohorts.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society